Novartis to Pay Up to $770 Million for Cadent Therapeutics, Enhancing Neuropsychiatric Pipeline

Novartis has agreed to buy Cambridge, Mass.-based Cadent Therapeutics for a possible $770 million, expanding its pipeline of treatments for cognitive and mood disorders.
Source: Drug Industry Daily